Dysregulation of MAPK and p53 signaling has been implicated in tumor progression.[38, 39] Our previous research showed that abnormal activation of MAPK signaling promotes the proliferation of tumor cells,[40] whereas inhibition of p53 activity promotes the progression and chemoresistance of CRC cells.[41] However, the crosstalk between these signaling pathways in oxaliplatin chemotherapy for CRC remains poorly understood. The gene discussed is TP53; the disease is neoplasm.